Respiratory diseases such as Asthma & COPD are becoming more common, especially in children, and the demand for continued advancements in drug discovery has grown significantly in recent years. It is estimated that the commercial drug development market will grow to $23 billion by 2014, with 300 million people in the world suffering from Asthma, COPD continuing to rise, and inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class.

Attend IQPC’s Asthma & COPD conference to Learn Strategies on How To:

• Theodore F. Reiss, MD, Vice President of Clinical Research, Merck Research Laboratories
• Nestor A. Molfino, MD, Vice President, Clinical Development, Respiratory Diseases, Allergy and Inflammation, MedImmune
• Heribert Staudinger, MD, Vice President, Clinical Development, Allergy, Respiratory and Immunology, Schering-Plough Research Institute
• Adam Wanner, MD, Professor, Principal Investigator, University of Miami Miller School of Medicine
• Mark Parry-Billings, PhD, Chief Executive Officer, Topigen
• Shahin Sanjar, PhD, Head, Pipeline Sourcing, Nycomed US Inc.
• Julie D Suman, PhD, President, NextBreath
• John Teeter, MD, Senior Director, Development Lead, Respiratory/Diabetes Emerging Markets, Pfizer Inc.
• Kevin B. Bacon, PhD, President, Founder and Chief Scientific Officer, Axikin Pharmaceuticals
• F. Scott Fleming, Sr. Vice President, Co-founder, MicroDose Therapeutix, Inc.
• Colin Scott, MD, Global Brand Medical Director, Novartis
• Alasdair Gaw, PhD, Director of Discovery Medicine for Respiratory and Inflammation, AstraZeneca
• Yi Wang, PhD, Head, Preclinical Sciences, Alexion Pharmaceuticals Inc.
• Bruce D. Sunstein, Co-founder, Partner, Bromberg & Sunstein LLP
• Navin L. Rao, PhD, Senior Scientist, Drug Discovery, Inflammation, Johnson & Johnson
• M. Allen McAlexander, PhD, Investigator, Respiratory CEDD, GlaxoSmithKline
• Lawrence de Garavilla, PhD, Research Fellow, Inflammation and Pulmonary Diseases Team, Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
• Jonathan E. Phillips, Ph.D, Principal Scientist, Respiratory Drug Discovery, Schering-Plough Research Institute

Who should attend?

Vice President, Director or Scientist working in the pharmaceutical or biotech industries within:

Respiratory Science Research & Development Inflammation Clinical Development Regulatory Affairs Pulmonology

Drug Discovery Respiratory Illness Inhalation Drug Delivery Project Management Preclinical Development Portfolio Management

If you are not yet ready to register, feel free to request a reminder nearer the time .

Conference Partners

Sponsors	Media Partners	IQ Partner

[ Register Now] · [ Next: Conference Day One: Wednesday, June 24, 2009 ]